Skip to main content

Table 1 Sample counts by tissue and prior chemotherapy exposure

From: Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

  Patients Samples (with an untreated sample from same patient)
   Solid tissue Ascites Total  
Primary/untreated 76 75 4 79  
Primary/treated 5 5 (0) 0 (0) 5 (0)  
Relapse/treated 23 6 (4) 24 (10) 30 (14)  
Total 92 86 (4) 28 (10) 114 (14)  
  Carboplatin Cisplatin Cyc. Etoposide Gemcitabine Paclitaxel
Primary/treated 5 (0) 0 (0) 0 (0) 0 (0) 1 (0) 4 (0)
Relapse/treated 30 (14) 5 (2) 10 (6) 1 (1) 17 (8) 30 (14)
Total 35 (14) 5 (2) 10 (6) 1 (1) 18 (8) 34 (14)
  1. Parentheses indicate chemotherapy-treated samples with a patient-matched primary/untreated sample. Cyc., cyclophosphamide